Lucid Diagnostics (LUCD) Liabilities and Shareholders Equity (2020 - 2026)

Lucid Diagnostics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $34.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 3.92% year-over-year to $34.1 million; the trailing twelve-month figure through Mar 2026 stood at $166.4 million (up 38.41% YoY), and the FY2025 full-year result was $40.4 million, up 31.68% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $34.1 million, down from $40.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $62.1 million in Q1 2022, with the low at $22.6 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $38.2 million across 5 years, with a median of $34.1 million in 2024.
• The largest YoY upside for Liabilities and Shareholders Equity was 1064.21% in 2022 against a maximum downside of 44.9% in 2022.
• Lucid Diagnostics' Liabilities and Shareholders Equity stood at $32.5 million in 2022, then declined by 16.12% to $27.3 million in 2023, then advanced by 12.63% to $30.7 million in 2024, then surged by 31.68% to $40.4 million in 2025, then dropped by 15.74% to $34.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $34.1 million (Q1 2026), $40.4 million (Q4 2025), and $53.2 million (Q3 2025), per Business Quant data.